MLYS:NSD-Mineralys Therapeutics, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 14.66

Change

0.00 (0.00)%

Market Cap

N/A

Volume

1.69M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 69.68B
ARGX argenx NV ADR

N/A

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.94B
ONC BeiGene, Ltd.

N/A

USD 28.70B
RPRX Royalty Pharma Plc

N/A

USD 19.31B
SMMT Summit Therapeutics PLC

N/A

USD 14.57B
UTHR United Therapeutics Corporatio..

N/A

USD 14.37B
INCY Incyte Corporation

N/A

USD 14.22B
MRNA Moderna Inc

N/A

USD 13.74B

ETFs Containing MLYS

BBC Virtus LifeSci Biotech Cl.. 1.42 % 0.79 %

N/A

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.09% 88% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.09% 88% B+ 91% A-
Trailing 12 Months  
Capital Gain 13.56% 83% B 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.56% 83% B 76% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.01% 57% F 52% F
Dividend Return 4.01% 56% F 49% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.59% 89% A- 64% D
Risk Adjusted Return 14.54% 67% D+ 48% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector